Combination epidermal growth factor receptor variant III peptide-pulsed dendritic cell vaccine with miR-326 results in enhanced killing on EGFRvIII-positive cells

The mutant Type III variant of epidermal growth factor receptor (EGFRvIII) is present in approximately one-third of glioblastoma (GBM) patients. It is never found in normal tissues; therefore, it represents a candidate target for GBM immunotherapy. PEPvIII, a peptide sequence from EGFRvIII, was desi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jianlong, Wang, Feng, Wang, Guangzhi, Sun, Ying, Cai, Jinquan, Liu, Xing, Zhang, Junhe, Lu, Xiaoyan, Li, Yongli, Chen, Meng, Chen, Lingchao, Jiang, Chuanlu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432254/
https://www.ncbi.nlm.nih.gov/pubmed/28412740
http://dx.doi.org/10.18632/oncotarget.15445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432254/
https://www.ncbi.nlm.nih.gov/pubmed/28412740
http://dx.doi.org/10.18632/oncotarget.15445

Ejemplares similares